Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia

Leukemia

Volumn 16, Issue 7, 2002, Pages 1302-1310

  Padro T ^a   Bieker, R ^a   Ruiz, S ^a   Steins, M ^a   Retzlaff, S ^a   Burger H ^b   Buchner T ^a   Kessler, T ^a   Herrera, F ^a   Kienast, J ^a   Muller Tidow C ^a   Serve, H ^a   Berdel, W E ^a   Mesters, R M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Angiogenesis; Vascular endothelial growth factor receptor 2

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTILEUKEMIC AGENT; CYTARABINE; DAUNORUBICIN; SEMAXANIB; TIOGUANINE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW; BONE MARROW BIOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA REMISSION; MALE; MICROVASCULATURE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR VASCULARIZATION;

EID: 0036053859     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402534     Document Type: Article

References (58)

1. Blood vessel formation: What is its molecular basis?
2. Evidence of increased angiogenesis in patients with acute myeloid leukemia
3. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia
4. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
5. Angiogenesis in myelodysplatic syndromes
6. Bone marrow angiogenesis and progression in multiple myeloma
7. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
8. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
9. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia
10. New agents for acute myelogenous leukemia
11. Angiogenesis in cancer and other diseases
12. Vascular endothelial growth factor (VEGF) and its receptors
13. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
14. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
15. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
16. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer
17. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer
18. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
19. Expression of vascular endothelial growth factor in renal carcinomas
20. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma
21. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice
22. Role of Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
23. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis
24. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth on several mouse and human tumors
25. Halting angiogenesis suppresses carcinoma cell invasion
26. Gioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
27. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia
28. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
29. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells
30. Vascular endothelial growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes
31. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis
32. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
33. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia
34. KDR receptor: A key marker defining hematopoietic stem cells
35. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation
36. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration
37. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group
38. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival
39. Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia
40. Report of the National Cancer Institute-sponsored Workshop on definitions of diagnosis and response in acute myeloid leukemia
41. Non-parametric estimation from incomplete observations
42. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and example
43. Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group
44. Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 as an antiapoptotic factor
45. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia
46. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent
47. Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias
48. Expression and secretion of vascular endothelial growth factor-A by cytokine-stimulated hematopoietic progenitor cells: Possible role in the hematopoietic microenvironment
49. Erythroblasts are a source of angiogenic factors
50. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
51. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
52. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice
53. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
54. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via VEGF receptor flt-1
55. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis
56. A role for hematopoietic stem cells in promoting angiogenesis
57. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization
58. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth